Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report
Cabozantinib provided long-term benefits for more than 3 years. We emphasize that the measurement of cabozantinib concentration in the blood may play a supporting role as an indicator of long-term response.
Authors
- Tatsuru Hiraga
- Masaru Kato (ORCID: https://orcid.org/0000-0002-6627-1773)
- Hiroshi Kanno (ORCID: https://orcid.org/0000-0003-3340-9462)
- Masaru Ishida
- S. Maruyama (ORCID: https://orcid.org/0009-0008-1386-8112)
Institutions
- SHOWA Medical University (JP)
- Bioanalytica (Switzerland) (CH)
- Saiseikai Yokohama Eastern Hospital (JP)
- Saiseikai Ibaraki Hospital (JP)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1159/000545249
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52